Clinical Trial

LIMIT Early Adiposity Rebound in Children

Study acronym: LIMIT
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2021 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Childhood obesity is a strong predictor of adult obesity with health and economic consequences for the individual and society. Adiposity rebound (AR) is a rise in the Body Mass Index occurring between 3-7 years. Early adiposity rebound (EAR) occurs at a median age of 2 years and is a risk factor for later obesity. Events happening in "the first 1,000 days" play a role in obesity development. One of the key elements in this crucial time window is the gut microbiome, a highly dynamic organ that is sensitive to environmental exposure being linked to obesity development. Prenatal (dietary/lifestyle maternal factors and environmental exposure) and postnatal determinants (the type of feeding, sleep patterns, speed of growth) and environmental obesogenic pollutants may influence the infant microbial colonization, thus increasing the risk of EAR onset. LIMIT will holistically identify the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with AR vs EAR, driving new mechanistic insights to create an EAR predictive model. The study will evaluate a group of 150 mother-infant pairs, during the first four years of life at different follow-up.
Trial Details
NCT Number NCT04960670
Lead Sponsor University of Pavia
Conditions Childhood Obesity, Life Style, Intestinal Microbiome
Enrollment 150 participants
Start Date 2021-12-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-07-14